 |
  
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
International News European Union: Panel Says European Drug Agency Should Approve Combination HIV Drug AtriplaOctober 22, 2007 Gilead Sciences Inc., Bristol-Myers Squibb Co., and Merck & Co. said Thursday the EU's Committee for Medicinal Products for Human Use, part of the European Medicines Agency, has recommended its once-a-day HIV drug Atripla be approved for sale. The panel said Atripla should be approved for adults who have not been treated with other HIV therapies. Atripla combines efavirenz, emtricitabine, and tenofovir. An agency ruling is expected by the end of 2007. Associated Press 10.18.2007  This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
|
 |
Email
Print-Friendly
Glossary
The Body: About The Body | Contact The Body | Content Policy | Content Providers | Advertise With Us | Site Map
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
The Body is a service of Remedy Health Media, LLC, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
